Jiaosheng announced Q1 earnings, biotech pharmaceutical sales performance is strong, and the chief financial officer is worried that tariffs will be levied by China up to $400 million

Pampered (Johnson & Johnson NYSE (JNJ) reported Q1 earnings, beating earnings expectations and raising its full-year sales forecast to stop at $154.07 at press time. According to FactSet, the biotech pharmaceutical giant reported EPS earnings of $2.77 per share on an adjusted basis, beating analysts' expectations of $2.69. Sales rose 2.4 percent to $21.9 billion in the quarter, slightly ahead of Wall Street's forecast of $21.6 billion. Operating sales are now expected to be $92 billion, compared to the previous forecast of $91.3 billion. Pampering expects sales to reach $91.4 billion, up from $89.6 billion previously. Even if the performance is growing steadily and the performance of Biotech Pharmaceutical is impressive, the CFO is still worried about the impact of China's retaliatory sanctions and tariffs.

A number of biotech pharmaceuticals have brought outstanding performance

Pampering adjusted its 2025 performance guidance, completed its acquisition of drug developer Intra-Cellular Therapies, and added Caplyta, a drug used to treat bipolar disorder and depression, to its portfolio.

The Innovative Drugs Division of Petite & Johnson achieved 4.2% growth, driven by sales of a small number of oncology drugs and treatments in immunology, neuroscience and cardiovascular. MedTech operating sales increased 4.1 percent, with net acquisitions and divestitives having a positive 2.8 percent impact.

The company also scored several regulatory victories during the quarter, including the U.S. Food and Drug Administration's approval of Tremfya for the treatment of Crohn's disease in adult patients. In Europe, Rybrevant is approved for the treatment of patients with certain types of non-small cell lung cancer.

The finance chief is worried about the impact of China's tariff sanctions and estimates that China will levy 400 million yuan

Joseph Wolk, the chief financial officer of Pampering, said that shipping products originating in the United States to China, China's tariffs will be as high as $400 million, accounting for about 70% of the total, which is the actual impact. So there are still many unpredictable wait-and-see tariffs on drugs. Uncertainty over drug tariffs continues to put pressure on investors. Johnson & Johnson shares have been trailing the S&P 500 for the past three years, rising 6.7% and the broader market down 8.1% in 2025. The potential appeal of P&C's stock is its resilience during recessions, and it offers a diverse product portfolio across the pharmaceutical, biotech and medtech sectors. Since President Trump announced the tariffs on April 2, shares are down 1.1 percent, while the S&P 500 is down 4.7 percent. While the latest earnings beat expectations as an encouraging sign, the tariff hurdles that Pampering needs to overcome are far greater than meeting Wall Street's expectations. Pure market observation, non-investment advice.

This article Announces Q1 Earnings, Strong Sales of Biotech Pharmaceuticals, Chief Financial Officer Fears Tariffs Will Be Imposed by China as Much as $400 Million First appeared in Chain News ABMedia.